We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Synthesis of Butein Analogues and their Anti-proliferative Activity Against Gefitinib-resistant Non-small Cell Lung Cancer (NSCLC) through Hsp90 Inhibition.
- Authors
Young Ho Seo; Ju Hui Jeong
- Abstract
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer representing 85% of lung cancer patients. Despite several EGFR-targeted drugs have been developed in the treatment of NSCLC, the clinical efficacy of these EGFR-targeted therapies is being challenged by the occurrence of drug resistance. In this regard, Hsp90 represents great promise as a therapeutic target of cancerous diseases due to its role in modulating and stabilizing numerous oncogenic proteins. Accordingly, inhibition of single Hsp90 protein simultaneously disables multiple signaling networks so as to overcome drug resistance in cancer. In this study, we synthesized a series of 11 butein analogues and evaluated their biological activities against gefitinib-resistant NSCLC cells (H1975). Our study indicated that analogue 1h inhibited the proliferation of H1975 cells, down-regulated the expression of Hsp90 client proteins, including EGFR, Met, Her2, Akt and Cdk4, and upregulated the expression of Hsp70. The result suggested that compound 1h disrupted Hsp90 chaperoning function and could serve a potential lead compound to overcome the drug resistance in cancer chemotherapy.
- Subjects
NON-small-cell lung carcinoma; LUNG cancer; EPIDERMAL growth factor receptors; DRUG resistance; ONCOGENIC proteins
- Publication
Bulletin of the Korean Chemical Society, 2014, Vol 35, Issue 5, p1294
- ISSN
0253-2964
- Publication type
Article
- DOI
10.5012/bkcs.2014.35.5.1294